EP2485740A1 - Verfahren zum verhindern oder behandeln von sarkopenie und muskelatrophie bei tieren - Google Patents

Verfahren zum verhindern oder behandeln von sarkopenie und muskelatrophie bei tieren

Info

Publication number
EP2485740A1
EP2485740A1 EP10822363A EP10822363A EP2485740A1 EP 2485740 A1 EP2485740 A1 EP 2485740A1 EP 10822363 A EP10822363 A EP 10822363A EP 10822363 A EP10822363 A EP 10822363A EP 2485740 A1 EP2485740 A1 EP 2485740A1
Authority
EP
European Patent Office
Prior art keywords
isoflavones
animal
preventing
administered
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10822363A
Other languages
English (en)
French (fr)
Other versions
EP2485740A4 (de
EP2485740B1 (de
Inventor
Yuanlong Pan
Sunil Kochhar
Serge André Dominique REZZI
Françoise-Pierre MARTIN
Emma Pere-Trepat
Sebastiano Collino
Francia Arce Vera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Publication of EP2485740A1 publication Critical patent/EP2485740A1/de
Publication of EP2485740A4 publication Critical patent/EP2485740A4/de
Application granted granted Critical
Publication of EP2485740B1 publication Critical patent/EP2485740B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents

Definitions

  • the invention relates generally to methods for preventing or treating sarcopenia and muscle atrophy and particularly to methods for using isoflavones for preventing or treating sarcopenia and muscle atrophy in animals.
  • Isoflavones are naturally occurring chemical compounds found in plants such as beans and legumes, particularly soy. Although the mechanism of action is unclear, isoflavones mimic the effects of estrogen and modulate estrogen metabolism. As a result, isoflavones are known to reduce tumor cell proliferation, induce tumor cell apoptosis, regulate hormone balance, and reduce the risks of breast and prostate cancer, heart disease, osteoporosis, and several other diseases and conditions. However, isoflavones are not known for preventing or treating sarcopenia or muscle atrophy.
  • sarcopenia During aging, there is a gradual decrease in the ability to maintain skeletal muscle function and mass. The condition is known as "sarcopenia.” The exact cause of sarcopenia is unknown, but may be due to a combination of the gradual failure of "satellite cells” that help to regenerate skeletal muscle fibers and a decrease in sensitivity to or the availability of critical secreted growth factors that are necessary to maintain muscle mass and ensure satellite cell survival. Methods for combating sarcopenia are known in the art. US7442706 disclose methods for treating sarcopenia with growth hormone secretagogues. US7232580 and US7138148 disclose the use of extracts of Ginkgo biloba for preparing a medicament for the treatment of sarcopenia.
  • muscle atrophy is defined as a decrease in the mass of the muscle. Muscle atrophy can be a partial or complete wasting away of muscle. When a muscle atrophies, it becomes weaker and, since the ability to exert force is related to mass, loses its ability to effectively support body functions, e.g., motion. Muscle atrophy can be caused by many factors, e.g., diseases such as cancer, AIDS, congestive heart disease, chronic obstructive pulmonary disease, renal failure, and severe burns. Often these animals suffer from "cachexia" and have a poor prognosis for good health or survival. Methods for combating muscle atrophy are known in the art. US20070122821 discloses antisense compositions and methods for treating muscle atrophy. US20060003959 discloses methods and agents for maintaining muscle mass and for preventing muscle atrophy and related biomarkers.
  • isoflavones are administered to the animals in amounts of from about 0.001 to about 10 grams per kilogram of body weight per day (g/kg/day) for as long as there is a need for preventing or treating sarcopenia and muscle atrophy.
  • FIG. 1 illustrates metabolic profiles obtained from the metabolomic or metabonomic analysis of blood plasma using typical acquisition conditions (standard, CPMG, diffusion-edited spectra) on a 600 MHz nuclear magnetic resonance (NMR) spectrometer.
  • FIG. 2 illustrates a two-dimensional (2D) projection of the median of the scores obtained from the first latent variable for each group of animals at different periods.
  • isoflavones means isoflavones and their natural or synthetic analogs, derivatives, precursors, and metabolites useful in the invention, including, but not limited to, isoflavones substituted with one or more lignans or coumestans, e.g., pinoresinol, lariciresinol, secoisolariciresinol, matairesinol, hydroxymatairesinol, syringaresinol, sesamin, enterodiol, enterolactone, and coumestrol.
  • lignans or coumestans e.g., pinoresinol, lariciresinol, secoisolariciresinol, matairesinol, hydroxymatairesinol, syringaresinol, sesamin, enterodiol, enterolactone, and coumestrol.
  • animal means any animal susceptible to or suffering from sarcopenia or muscle atrophy, including human, avian, bovine, canine, equine, feline, hicrine, lupine, murine, ovine, or porcine animals.
  • aging means being of advanced age such that an animal is considered to be susceptible to sarcopenia.
  • the term "companion animal” means domesticated animals such as cats, dogs, rabbits, guinea pigs, ferrets, hamsters, mice, gerbils, horses, cows, goats, sheep, donkeys, pigs, and the like.
  • dietary supplement means a product that is intended to be ingested in addition to a normal animal diet.
  • Dietary supplements may be in any form, e.g., solid, liquid, gel, tablet, capsule, powder, and the like. Preferably they are provided in convenient dosage forms, e.g., in sachets. Dietary supplements can be provided in bulk consumer packages such as bulk powders, liquids, gels, or oils. Similarly such supplements can be provided in bulk quantities to be included in other food items such as snacks, treats, supplement bars, beverages, and the like.
  • the term "regular basis" means that the isoflavones of the invention are administered to the animal on a regular and periodic basis over time.
  • the isoflavones can be administered monthly, weekly, or daily as appropriate for the animal. More frequent administration such as twice or three times daily is preferred in certain embodiments.
  • Ranges are used herein as shorthand to avoid having to list and describe each and every value within the range. Any appropriate value within the range can be selected, where appropriate, as the upper value, lower value, or the terminus of the range.
  • the invention provides methods for preventing or treating sarcopenia.
  • the methods comprise administering to the animals a sarcopenia preventing or treating amount of one or more isoflavones.
  • the invention provides methods for preventing or treating muscle atrophy.
  • the methods comprise administering to the animals a muscle atrophy preventing or treating amount of one or more isoflavones.
  • the inventions are based upon the discovery that isoflavones can be used to ameliorate changes in muscle caused by aging or caused by diseases or conditions that cause muscle atrophy.
  • the animals are animals of any species or kind that are susceptible to or suffering from a disease or condition that causes sarcopenia or muscle atrophy, including animals of any age, species, health condition, and the like.
  • the animals are aging animals susceptible to or suffering from sarcopenia.
  • the animals are animals susceptible to or suffering from a disease or condition that causes muscle atrophy, e.g., cancer, AIDS, congestive heart disease, chronic obstructive pulmonary disease, renal failure, severe burns, and the like.
  • the isoflavones are any isoflavones known to skilled artisans.
  • the isoflavones are selected from the group consisting of isoflavones in the form of aglycons, glucosides, acetylglucosides, and malonylglucosides.
  • the isoflavones are selected from the group consisting of bhttp://en.vvikipedia.org/wiki/Flavoxateiochanin A, daidzein, daidzin, glycitein, formononetin, equol, genistein, irilone, luteone, prunetin, pratensein, and glycitinn.
  • the isoflavones are soy isoflavones obtained from soy or administered to the animal by feeding soy or soy extracts to the animal.
  • the isoflavones are isoflavones substituted with one or more lignans or coumestans such as pinoresinol, lariciresinol, secoisolariciresinol, matairesinol, hydroxymatairesinol, syringaresinol, sesamin, enterodiol, enterolactone, and coumestrol.
  • the isoflavones are administered to the animals as required to function in the invention, e.g., preventing or treating sarcopenia or muscle atrophy.
  • Administration amounts can easily be determined by skilled artisans, generally based upon the isoflavone(s) to be administered, the animal, the health conditions and status of the animal, the administration purpose, and the like.
  • the isoflavones are administered to the animals on a regular basis, preferably on a weekly basis, most preferably in a daily basis.
  • the isoflavones are administered to the animals in amounts of from about 5 mg/day to about 5000 mg/day, preferably from 10 mg/day to about 2000 mg/day, more preferably from about 30 mg/day to about 500 mg/day, most preferably from about 50 mg/day to about 300 mg/day. In other embodiments, the isoflavones are administered to the animals in amounts of from about 0.001 to about 10 grams per kilogram of body weight per day (g/kg/day), preferably from about 0.05 to about 5 g/kg/day, most preferably from about 0.01 to about 1 g/kg/day.
  • the isoflavones are administered for as long as there is a need for preventing or treating sarcopenia or muscle atrophy. For aging animals, isoflavone administration generally is needed for the remainder of the animal's life.
  • the isoflavones are administered to the animal in any suitable manner known to skilled artisans.
  • the isoflavones are administered to the animal in a composition containing isoflavones, preferably compositions intended for oral administration.
  • the isoflavones are administered to the animal as a dietary supplement.
  • the isoflavones are administered to the animal in a food composition.
  • a food composition is formulated to provide "complete and balanced" nutrition for an animal, preferably a companion animal, according to standards established by the Association of American Feed Control Officials (AAFCO).
  • the food compositions are formulated as a companion animal food composition, including a dog or cat food composition.
  • the dietary supplements or food compositions are formulated to contain one or more isoflavones in amounts sufficient to administer the desirable amounts of isoflavones to the animal, i.e. , amounts of from about 5 mg to about 5000 mg or amounts sufficient to administer from about 0.001 to about 10 g kg/day.
  • the animal is a human. In others, the animal is a companion animal, preferably a dog or a cat.
  • the invention provides a package comprising one or more isoflavones and a label affixed to the package containing a word or words, picture, design, acronym, slogan, phrase, or other device, or combination thereof that indicates that the contents of the package contains isoflavones with beneficial properties relating to preventing or treating sarcopenia or muscle atrophy.
  • a device comprises the words “prevents sarcopenia”, “treats atrophy”, “prevents or treats muscle wasting", or an equivalent expression printed on the package.
  • Any package or packaging material suitable for containing the composition is useful in the invention, e.g., bag, box, bottle, can, pouch, and the like manufactured from paper, plastic, foil, metal, and the like.
  • the package contains a food composition adapted for a particular animal such as a human, canine, or feline, as appropriate for the label, preferably a companion animal food composition for dogs or cats.
  • the package is a can or pouch comprising a food composition useful for the invention.
  • the invention provides a means for communicating information about or instructions for one or more of (1) using isoflavones for preventing or treating sarcopenia; (2) using isoflavones for preventing or treating muscle atrophy; (3) contact information for consumers to use if they have a question about the methods of the invention, e.g., about administering or using isoflavones for preventing or treating sarcopenia or muscle atrophy; and (4) nutritional information about isoflavones.
  • Useful instructions include administration amounts and frequency for isoflavones.
  • the communication means is useful for instructing on the benefits of using the invention and communicating the approved methods for administering the isoflavones to an animal.
  • the means comprises one or more of a physical or electronic document, digital storage media, optical storage media, audio presentation, audiovisual display, or visual display containing the information or instructions.
  • the means is selected from the group consisting of a displayed website, a visual display kiosk, a brochure, a product label, a package insert, an advertisement, a handout, a public announcement, an audiotape, a videotape, a DVD, a CD- ROM, a computer readable chip, a computer readable card, a computer readable disk, a USB device, a Fire Wire device, a computer memory, and any combination thereof.
  • the invention provides for the use of one or more isoflavones to prepare a medicament.
  • the invention provides for the use of isoflavones to prepare a medicament for one or more of preventing or treating sarcopenia or muscle atrophy.
  • medicaments are prepared by admixing a compound or composition with excipients, buffers, binders, plasticizers, colorants, diluents, compressing agents, lubricants, flavorants, moistening agents, and other ingredients known to skilled artisans to be useful for producing medicaments and formulating medicaments that are suitable for administration to an animal.
  • the plasma ⁇ NMR spectra i.e. , the metabolite profiles
  • metabolic information i.e. , biomarkers
  • Distinct metabolic trajectories were observed in animals that received isoflavones and control animals over time, as shown in Figure 2.
  • the data is shown in Table 1 .
  • the data show that an increase in muscle breakdown is prevented in animals that received the isoflavones. There was no increase in plasma circulating concentrations of leucine, valine, threonine, histidine, methionine, and 3-methyl- histidine. The results show that isoflavones are useful for preventing or treating muscle breakdown and wasting characteristic of sarcopenia and muscle atrophy caused by disease or other conditions.
  • the R 2 X and R 2 Y values show how much of the variation in the data set X (NMR data) and Y (group assignment) is explained by the model, respectively.
  • the Q 2 Y value represents the predictability of the model and relates to its statistical validity or robustness.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
EP10822363.7A 2009-10-09 2010-10-08 Verfahren zum verhindern oder behandeln von sarkopenie und muskelatrophie bei tieren Active EP2485740B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27863309P 2009-10-09 2009-10-09
PCT/US2010/002722 WO2011043827A1 (en) 2009-10-09 2010-10-08 Methods for preventing or treating sarcopenia and muscle atrophy in animals

Publications (3)

Publication Number Publication Date
EP2485740A1 true EP2485740A1 (de) 2012-08-15
EP2485740A4 EP2485740A4 (de) 2013-04-03
EP2485740B1 EP2485740B1 (de) 2018-08-29

Family

ID=43857050

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10822363.7A Active EP2485740B1 (de) 2009-10-09 2010-10-08 Verfahren zum verhindern oder behandeln von sarkopenie und muskelatrophie bei tieren

Country Status (12)

Country Link
US (1) US9301941B2 (de)
EP (1) EP2485740B1 (de)
JP (1) JP6122638B2 (de)
CN (1) CN102573857A (de)
AU (1) AU2010303872B2 (de)
BR (1) BR112012008238A2 (de)
CA (1) CA2776950C (de)
ES (1) ES2688447T3 (de)
IN (1) IN2012DN02624A (de)
MX (1) MX2012004118A (de)
RU (1) RU2558534C2 (de)
WO (1) WO2011043827A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11090313B2 (en) 2010-05-20 2021-08-17 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
CN106822153B (zh) * 2011-06-06 2019-12-17 爱荷华大学研究基金会 用于抑制肌萎缩的方法
CN105796546B (zh) * 2011-10-18 2020-03-03 株式会社爱茉莉太平洋 包含丁香脂素的sirt1活化剂
WO2015166887A1 (ja) * 2014-04-28 2015-11-05 サントリーホールディングス株式会社 ケルセチン配糖体を含有する筋萎縮抑制剤
WO2016130981A1 (en) 2015-02-13 2016-08-18 Mars, Incorporated Pet food feeding system
KR20170002846A (ko) 2015-06-30 2017-01-09 (주)아모레퍼시픽 콩잎 추출물을 유효성분으로 함유하는 근질환 억제 및 예방용 조성물
GB201522304D0 (en) 2015-12-17 2016-02-03 Mars Inc Food product for reducing muscle breakdown
CN108635571B (zh) * 2018-07-19 2021-10-22 西安交通大学医学院第一附属医院 鸢尾素(irisin)在制备预防及治疗重症急性胰腺炎药物中的应用
WO2021065661A1 (ja) * 2019-10-04 2021-04-08 サントリーホールディングス株式会社 筋肉量の低下抑制、低下予防、維持、回復又は増加用組成物
KR102623198B1 (ko) * 2020-02-26 2024-01-10 한국 한의학 연구원 돌콩 추출물을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소의 예방, 개선 또는 치료용 조성물
RU2756154C1 (ru) * 2020-11-13 2021-09-28 Митхат Зульфугар-Оглы Гасанов Способ диагностики саркопении у пациентов с хронической болезнью почек 5д стадии, получающих лечение программным гемодиализом
WO2023140407A1 (ko) * 2022-01-21 2023-07-27 경상국립대학교병원 쿠메스트롤을 포함하는 근감소증 예방 또는 치료용 약학 조성물

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4163746A (en) * 1973-07-09 1979-08-07 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Metabolic 5-methyl-isoflavone-derivatives, process for the preparation thereof and compositions containing the same
US20030021858A1 (en) * 2000-05-22 2003-01-30 Bababunmi Enitan A. Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease
EP1329222A1 (de) * 2001-12-18 2003-07-23 Daicho Kikaku Incorporated Company Isoflavonzusammensetzungen zur medizinischen Anwendung
WO2005089567A1 (en) * 2004-03-17 2005-09-29 Nestec S.A. Compositions and methods for reducing or preventing obesity
WO2007134867A2 (en) * 2006-05-24 2007-11-29 Dsm Ip Assets B.V. Treating muscular disorders and improving muscular function

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1192943A3 (de) * 2000-09-28 2002-11-27 Pfizer Products Inc. Verwendung von Sekretionsfördermitteln für Wachstumshormone in Verbindung mit Körpertraining
AUPR846401A0 (en) * 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
WO2005007676A2 (en) 2003-07-10 2005-01-27 Rajadhyaksha V J Glycopeptides for the treatment of als and other metabolic and autoimmune disorders
EP1734950A4 (de) 2004-01-29 2010-06-16 Elixir Pharmaceuticals Inc Behandlung einer viruserkrankung
PT2054049E (pt) * 2006-08-24 2016-06-02 Univ Tennessee Res Found Acilanilidas substituídas e métodos de utilização das mesmas

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4163746A (en) * 1973-07-09 1979-08-07 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Metabolic 5-methyl-isoflavone-derivatives, process for the preparation thereof and compositions containing the same
US20030021858A1 (en) * 2000-05-22 2003-01-30 Bababunmi Enitan A. Formulation and method for treating skeletal muscle degeneration caused by malnutrition and disease
EP1329222A1 (de) * 2001-12-18 2003-07-23 Daicho Kikaku Incorporated Company Isoflavonzusammensetzungen zur medizinischen Anwendung
WO2005089567A1 (en) * 2004-03-17 2005-09-29 Nestec S.A. Compositions and methods for reducing or preventing obesity
WO2007134867A2 (en) * 2006-05-24 2007-11-29 Dsm Ip Assets B.V. Treating muscular disorders and improving muscular function

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AUBERTIN-LEHEUDRE M ET AL: "Six months of isoflavone supplement increases fat-free mass in obese-sarcopenic postmenopausal women: a randomized double-blind controlled trial", EUROPEAN JOURNAL OF CLINICAL NUTRITION, NATURE PUBLISHING GROUP, GB, vol. 61, no. 12, 1 December 2007 (2007-12-01), pages 1442-1444, XP009100571, ISSN: 0954-3007, DOI: 10.1038/SJ.EJCN.1602695 *
See also references of WO2011043827A1 *

Also Published As

Publication number Publication date
EP2485740A4 (de) 2013-04-03
EP2485740B1 (de) 2018-08-29
IN2012DN02624A (de) 2015-05-22
MX2012004118A (es) 2012-05-08
RU2012118686A (ru) 2013-11-20
WO2011043827A1 (en) 2011-04-14
RU2558534C2 (ru) 2015-08-10
US9301941B2 (en) 2016-04-05
JP2013507361A (ja) 2013-03-04
AU2010303872B2 (en) 2016-06-23
JP6122638B2 (ja) 2017-04-26
US20120238515A1 (en) 2012-09-20
BR112012008238A2 (pt) 2017-06-06
CN102573857A (zh) 2012-07-11
CA2776950C (en) 2023-11-21
ES2688447T3 (es) 2018-11-02
AU2010303872A1 (en) 2012-04-19
CA2776950A1 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
AU2010303872B2 (en) Methods for preventing or treating sarcopenia and muscle atrophy in animals
AU2006279429B2 (en) Methods and compositions for the prevention and treatment of kidney disease
AU2009282482B2 (en) Methods for enhancing energy metabolism
AU2012243210B2 (en) Methods for regulating sirtuin gene expression
AU2006236345B2 (en) Methods and compositions for the prevention and treatment of kidney disease
JP5227195B2 (ja) 骨成長の誘発及び骨損失の抑制のための組成物及び方法
WO2012145281A2 (en) Methods and compositions suitable for preventing and treating hyperleptinemia
US10143219B2 (en) Nutritional supplement/feed formula and methods of use thereof to reduce development of Osteochondrosis Dissecans (OCD) lesions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120330

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130306

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/343 20060101ALI20130228BHEP

Ipc: A23L 1/30 20060101ALI20130228BHEP

Ipc: A61P 21/00 20060101ALI20130228BHEP

Ipc: A23K 1/18 20060101ALI20130228BHEP

Ipc: A23L 1/29 20060101ALI20130228BHEP

Ipc: A61K 31/352 20060101ALI20130228BHEP

Ipc: A61K 31/35 20060101ALI20130228BHEP

Ipc: A23K 1/16 20060101AFI20130228BHEP

Ipc: A61K 31/353 20060101ALI20130228BHEP

Ipc: A61K 31/366 20060101ALI20130228BHEP

17Q First examination report despatched

Effective date: 20140923

17Q First examination report despatched

Effective date: 20140924

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602010053188

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0031785000

Ipc: A61K0031343000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/343 20060101AFI20180419BHEP

Ipc: A61K 31/366 20060101ALI20180419BHEP

Ipc: A23K 20/10 20160101ALI20180419BHEP

Ipc: A61K 31/35 20060101ALI20180419BHEP

Ipc: A61K 31/352 20060101ALI20180419BHEP

Ipc: A61P 21/00 20060101ALI20180419BHEP

Ipc: A61K 31/353 20060101ALI20180419BHEP

INTG Intention to grant announced

Effective date: 20180522

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1034324

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180915

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010053188

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2688447

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20181102

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181129

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180829

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181130

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181229

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181129

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180829

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180829

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180829

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1034324

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180829

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180829

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180829

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180829

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180829

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180829

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180829

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180829

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180829

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010053188

Country of ref document: DE

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20181031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181008

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180829

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: SOCIETE DES PRODUITS NESTLE S.A.; CH

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE; FORMER OWNER NAME: NESTEC S.A.

Effective date: 20190620

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: SOCIETE DES PRODUITS NESTLE S.A.

26N No opposition filed

Effective date: 20190531

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20190801 AND 20190807

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181031

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181031

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181031

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181008

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602010053188

Country of ref document: DE

Representative=s name: MITSCHERLICH, PATENT- UND RECHTSANWAELTE PARTM, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602010053188

Country of ref document: DE

Owner name: SOCIETE DES PRODUITS NESTLE S.A., CH

Free format text: FORMER OWNER: NESTEC S.A., VEVEY, CH

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180829

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180829

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180829

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20101008

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230527

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230915

Year of fee payment: 14

Ref country code: IT

Payment date: 20230913

Year of fee payment: 14

Ref country code: IE

Payment date: 20230912

Year of fee payment: 14

Ref country code: GB

Payment date: 20230831

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230911

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231108

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20230830

Year of fee payment: 14